Axa S.A. Novavax Inc Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $1.69 Million - $3.46 Million	-24,220 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $1.7 Million - $2.75 Million	-12,607 Reduced 34.23%	24,220 $3.47 Million
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $241,096 - $366,906	1,356 Added 3.82%	36,827 $7.64 Million
Q2 2021 Aug 13, 2021	SELL	$121.0 - $257.67 $3.96 Million - $8.44 Million	-32,753 Reduced 48.01%	35,471 $7.53 Million
Q1 2021 May 14, 2021	BUY	$112.98 - $319.93 $7.71 Million - $21.8 Million	68,224 New	68,224 $12.4 Million
Q2 2020 Aug 14, 2020	SELL	$13.86 - $83.61 $471,240 - $2.84 Million	-34,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.93 - $16.0 $133,620 - $544,000	34,000 New	34,000 $462,000

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.